Eterna Therapeutics Inc
ERNA1.560USD
0.000
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
81.51MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Eterna Therapeutics Inc Unternehmen
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
Unternehmensinformationen
BörsenkürzelERNA
Name des UnternehmensErnexa Therapeutics Inc
IPO-datumAug 29, 1991
CEOMr. Sanjeev Luther
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeAug 29
Addresse1035 Cambridge Street
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02141
Telefon16177986700
Websitehttps://www.ernexatx.com/
BörsenkürzelERNA
IPO-datumAug 29, 1991
CEOMr. Sanjeev Luther
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Feb 24
Währung: USDAktualisiert: Mon, Feb 24
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
Nach RegionUSD
Name
Umsatz
Anteil
United States
5.48M
94.48%
Canada
320.00K
5.52%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
Aktionärsstatistik
Aktualisiert: Thu, Jul 31
Aktualisiert: Thu, Jul 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Aktionäre
Aktionäre
Anteil
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
48.37%
Corporation
12.51%
Investment Advisor/Hedge Fund
0.52%
Hedge Fund
0.27%
Investment Advisor
0.24%
Research Firm
0.16%
Venture Capital
0.04%
Other
37.90%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
52
4.57M
62.09%
+1.56M
2025Q1
56
2.92M
80.53%
+838.33K
2024Q4
54
33.02M
64.27%
+30.12M
2024Q3
67
2.84M
52.46%
-257.40K
2024Q2
83
2.52M
46.53%
-624.19K
2024Q1
121
2.54M
46.88%
-584.16K
2023Q4
126
2.36M
43.79%
-543.57K
2023Q3
142
2.77M
52.76%
-391.46K
2023Q2
146
2.77M
53.56%
-376.86K
2023Q1
150
2.98M
67.03%
+101.08K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cherington (Charles)
2.78M
37.73%
+1.42M
+104.20%
Jun 09, 2025
Freebird Partners LP
414.10K
5.63%
--
--
Apr 14, 2025
Halpern (John D)
390.45K
5.3%
--
--
Apr 14, 2025
Denny George P Iii
332.71K
4.52%
+3.36K
+1.02%
Apr 14, 2025
Regolith Capital Investments LP
222.88K
3.03%
--
--
Apr 14, 2025
IAF, LLC
217.03K
2.95%
--
--
Apr 14, 2025
Purchase Capital LLC
66.67K
0.91%
+66.67K
--
Dec 31, 2024
Singer (Nicholas Jason)
54.00K
0.73%
+54.00K
--
Dec 31, 2024
Geode Capital Management, L.L.C.
19.54K
0.27%
+2.39K
+13.93%
Mar 31, 2025
Corient Private Wealth LLC
17.52K
0.24%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Datum
Art
Verhältnis
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
